Methotrexate alone, with step up to other therapies only if a response is not achieved, is a reasonable starting strategy for treating "poor prognosis" rheumatoid arthritis (RA), said James O'Dell, MD, at the annual scientific meeting of the American College of Rheumatology, Chicago.
Methotrexate alone, with step up to other therapies only if a response is not achieved, is a reasonable starting strategy for treating "poor prognosis" rheumatoid arthritis (RA), said James O'Dell, MD, at the annual scientific meeting of the American College of Rheumatology, Chicago.
More than one-fourth of patients who were started on methotrexate alone achieved clinical remission at week 24, and this remission was dur-able out to 2 years, in a randomized 4-treatment arm study.
In the Treatment of Early Aggressive RA (TEAR) trial, 755 patients were randomly assigned to 1 of 4 treatment arms:
In the primary analysis, at 24 weeks, patients assigned to combination treatment had clinically superior responses on DAS28, but the difference was lost by 36 weeks after monotherapy nonresponders stepped up to double or triple therapy.
Twenty-eight percent of patients on methotrexate alone achieved DAS28 remission at week 24, and these responders maintained a durable response to 2 years.
There was an immediate advantage to using all drugs together when measuring the outcome (DAS28 remission) at 24 weeks, "but if you measure outcome between 1 and 2 years, there is no advantage clinically to doing that," said Dr O'Dell, professor of internal medicine, division of rheumatology, University of Nebraska Medical Center, Omaha.
Radiographic outcomes between the 4 treatment arms from treatment initiation to week 102 were nearly identical. "There was no radiographic penalty for waiting to make the decision clinically [to step up after initial methotrexate therapy]," he said.
In the group assigned to methotrexate monotherapy, 72% had a DAS28 >3.2 and stepped up to either etanercept or sulfasalazine/hydroxychloroquine, while 28% had low disease activity (DAS28 ≤3.2) and remained on methotrexate monotherapy.
Patients that stepped up had significantly more tender and swollen joints and a higher mean DAS28 score than those who did not require step-up therapy.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.